Novartis licenses small molecule treatment for a genetic ultra-rare disease
Novartis enters a licensing and development agreement with Pharming group for ultra-rare disease treatment for more than $20m.
Novartis enters a licensing and development agreement with Pharming group for ultra-rare disease treatment for more than $20m.
VirTrial is providing free training and certification to SCRS members as it expects most future protocols to include a telemedicine component.
SGS’ OneVision initiative is working to standardize record-keeping across the global life sciences industry in an aim to accelerate laboratory testing, development, and eliminate paper-based systems.
FDA approves the third anti-TB drug in more than 40 years after the compound showed significantly higher success rates in patients with multi drug-resistant and extensively drug-resistant TB.
Signant Health’s new partner program was established to help reduce scope creep and prevent miscommunication between CROs and sponsors, says VP.
Iqvia today launches its new patient portal, designed to support clinical trial participants throughout the process with a “direct connection to the clinical research environment,” says company executive.